Overview

• A randomized phase 2 trial led by the Icahn School of Medicine at Mount Sinai found a 52% reduction in the risk of progression or death versus carboplatin alone.
• The regimen was reported as well tolerated in the metastatic setting with no unexpected safety concerns.
• Participants had triple-negative breast cancer previously treated up to three times before enrollment.
• The strategy targets mTOR pathway activation often seen in tumors with PTEN loss, providing a clear biological rationale.
• Findings were published in Breast Cancer Research and Treatment, and Novartis supplied everolimus for the study.